WO2004064866A1 - カルノシナーゼ阻害剤とl−カルノシン類との併用および組成物 - Google Patents
カルノシナーゼ阻害剤とl−カルノシン類との併用および組成物 Download PDFInfo
- Publication number
- WO2004064866A1 WO2004064866A1 PCT/JP2004/000351 JP2004000351W WO2004064866A1 WO 2004064866 A1 WO2004064866 A1 WO 2004064866A1 JP 2004000351 W JP2004000351 W JP 2004000351W WO 2004064866 A1 WO2004064866 A1 WO 2004064866A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lunosine
- alanine
- carnosine
- derivative
- carnosinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Food Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Addiction (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/542,109 US20060116328A1 (en) | 2003-01-20 | 2004-01-16 | Combined use of carnosinase inhibitor with l-carnosines and composition |
JP2005508063A JPWO2004064866A1 (ja) | 2003-01-20 | 2004-01-16 | カルノシナーゼ阻害剤とl−カルノシン類との併用および組成物 |
EP04702856A EP1586332A4 (en) | 2003-01-20 | 2004-01-16 | COMBINED USE OF CARNOSINAS INHIBITOR WITH L-CARNOSINES AND COMPOSITION |
US14/094,155 US20140086855A1 (en) | 2003-01-20 | 2013-12-02 | Combined use of a carnosinase inhibitor with l-carnosine or its related substance and a composition containing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-10639 | 2003-01-20 | ||
JP2003010639 | 2003-01-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/542,109 A-371-Of-International US20060116328A1 (en) | 2003-01-20 | 2004-01-16 | Combined use of carnosinase inhibitor with l-carnosines and composition |
US14/094,155 Division US20140086855A1 (en) | 2003-01-20 | 2013-12-02 | Combined use of a carnosinase inhibitor with l-carnosine or its related substance and a composition containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004064866A1 true WO2004064866A1 (ja) | 2004-08-05 |
Family
ID=32767262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/000351 WO2004064866A1 (ja) | 2003-01-20 | 2004-01-16 | カルノシナーゼ阻害剤とl−カルノシン類との併用および組成物 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20060116328A1 (ja) |
EP (1) | EP1586332A4 (ja) |
JP (3) | JPWO2004064866A1 (ja) |
WO (1) | WO2004064866A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1506776A1 (de) * | 2003-08-12 | 2005-02-16 | KeyNeurotek AG | Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention von chronischen neurodegenerativen Erkrankungen |
JP2006312597A (ja) * | 2005-05-09 | 2006-11-16 | Shiseido Co Ltd | 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物 |
JP2009120564A (ja) * | 2007-11-16 | 2009-06-04 | Maruha Nichiro Foods Inc | ヒアルロン酸産生促進物質 |
WO2010005077A1 (ja) * | 2008-07-11 | 2010-01-14 | 財団法人ヒューマンサイエンス振興財団 | パーキンソン病の疾患関連たんぱく質およびその使用 |
US7776364B2 (en) | 2006-03-24 | 2010-08-17 | Advanced Scientific, Llc | Non-surgical method for treating cataracts in mammals including man |
JP2010208989A (ja) * | 2009-03-10 | 2010-09-24 | Fancl Corp | 抗不安剤 |
WO2011078204A1 (ja) * | 2009-12-24 | 2011-06-30 | 浜理薬品工業株式会社 | 高脂血症の予防または治療剤、および抗疲労剤 |
JP2012021026A (ja) * | 2011-10-07 | 2012-02-02 | Shiseido Co Ltd | 不全角化抑制剤、毛穴縮小剤及び肌荒れ防止・改善剤 |
JP2013176327A (ja) * | 2012-02-28 | 2013-09-09 | Sapporo Breweries Ltd | 麦芽飲料、香味改善剤及びこれらに関する方法 |
WO2014140890A2 (en) | 2013-03-13 | 2014-09-18 | Neocutis Sa | Peptides for skin rejuvenation and methods of using the same |
WO2017104777A1 (ja) * | 2015-12-16 | 2017-06-22 | サントリーホールディングス株式会社 | カルノシンジペプチダーゼ阻害用組成物 |
CN108578678A (zh) * | 2018-03-13 | 2018-09-28 | 孟斯琴 | 一种抗癫痫药物组合物及其制备方法 |
WO2022167569A1 (en) * | 2021-02-04 | 2022-08-11 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic composition |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2449554C2 (ru) * | 2006-02-01 | 2012-05-10 | Нестек С.А. | Пищевые системы и способы увеличения долголетия |
WO2008057802A2 (en) * | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
EP2052735B1 (en) | 2007-10-22 | 2016-05-11 | Lytone Enterprise, Inc. | Pharmaceutical composition and kit comprising anserine for rapidly reducing uric acid in blood |
WO2012142474A2 (en) * | 2011-04-13 | 2012-10-18 | Thermolife International, Llc | N-acetyl beta alanine methods of use |
ITMI20121586A1 (it) * | 2012-09-24 | 2014-03-25 | N G C Medical Spa | L-carnosina per il trattamento delle miopatia congenita mitocondriale e della sindrome della fatica muscolare cronica |
JP2016135746A (ja) * | 2015-01-23 | 2016-07-28 | 学校法人順天堂 | 新規トリペプチド及びそれを含有する医薬 |
WO2017010133A1 (ja) * | 2015-07-16 | 2017-01-19 | サントリーホールディングス株式会社 | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 |
WO2017010537A1 (ja) * | 2015-07-16 | 2017-01-19 | サントリーホールディングス株式会社 | 環状ジペプチド含有血清カルノシン分解酵素阻害用組成物 |
CN105461632B (zh) * | 2016-01-04 | 2018-01-09 | 湖北泓肽生物科技有限公司 | 一种n‑乙酰‑l‑肌肽的制备方法 |
JP2020031556A (ja) * | 2018-08-28 | 2020-03-05 | 浜理薬品工業株式会社 | 筋損傷抑制剤 |
US11865139B2 (en) | 2020-11-12 | 2024-01-09 | Thermolife International, Llc | Method of treating migraines and headaches |
CN112870182A (zh) * | 2021-03-18 | 2021-06-01 | 中南大学 | 紫苏醇及其衍生物在制备减轻化疗副作用药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58164511A (ja) * | 1982-03-25 | 1983-09-29 | Kaneshiro Nagai | 老人性▲そう▼痒症の治療剤 |
JPS58164516A (ja) * | 1982-03-25 | 1983-09-29 | Kaneshiro Nagai | 湿疹性皮膚疾患および薬疹治療剤 |
WO1996036348A1 (en) * | 1995-05-19 | 1996-11-21 | Farmila-Farmaceutici Milano S.R.L. | Pharmaceutical and/or dietetic compositions with antioxidant activity containing carnosine or derivatives and branched amino acids |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6314728A (ja) * | 1986-07-03 | 1988-01-21 | Zeria Shinyaku Kogyo Kk | 肝障害の予防、治療剤 |
US4837012A (en) * | 1987-06-19 | 1989-06-06 | S. C. Johnson & Son, Inc. | Hair reviver composition containing film-forming amino acids |
JP2811353B2 (ja) * | 1990-07-06 | 1998-10-15 | ゼリア新薬工業株式会社 | 炎症性腸疾患予防・治療剤 |
FR2701948B1 (fr) | 1993-02-22 | 1996-07-26 | Exsymol Sa | Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires. |
IT1270905B (it) * | 1993-10-15 | 1997-05-13 | Bruschettini Srl | Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta |
US5965596A (en) * | 1997-08-12 | 1999-10-12 | Harris; Roger | Methods and compositions for increasing the anaerobic working capacity in tissue |
JPH1112191A (ja) | 1997-06-24 | 1999-01-19 | Hamari Yakuhin Kogyo Kk | エタノール吸収阻害剤 |
US6903136B2 (en) * | 2002-04-22 | 2005-06-07 | Experimental And Applied Sciences, Inc. | Food supplements containing 4-hydroxyisoleucine and creatine |
JP2006504701A (ja) * | 2002-09-30 | 2006-02-09 | マーク・エー・バビザイェフ | 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段 |
US6899904B2 (en) * | 2002-11-14 | 2005-05-31 | The Meow Mix Company | Pet food compositions having electrostatically charged ingredient |
-
2004
- 2004-01-16 EP EP04702856A patent/EP1586332A4/en not_active Withdrawn
- 2004-01-16 WO PCT/JP2004/000351 patent/WO2004064866A1/ja active Application Filing
- 2004-01-16 US US10/542,109 patent/US20060116328A1/en not_active Abandoned
- 2004-01-16 JP JP2005508063A patent/JPWO2004064866A1/ja active Pending
-
2010
- 2010-10-22 JP JP2010237838A patent/JP2011068652A/ja active Pending
-
2013
- 2013-10-07 JP JP2013210364A patent/JP2014012735A/ja active Pending
- 2013-12-02 US US14/094,155 patent/US20140086855A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58164511A (ja) * | 1982-03-25 | 1983-09-29 | Kaneshiro Nagai | 老人性▲そう▼痒症の治療剤 |
JPS58164516A (ja) * | 1982-03-25 | 1983-09-29 | Kaneshiro Nagai | 湿疹性皮膚疾患および薬疹治療剤 |
WO1996036348A1 (en) * | 1995-05-19 | 1996-11-21 | Farmila-Farmaceutici Milano S.R.L. | Pharmaceutical and/or dietetic compositions with antioxidant activity containing carnosine or derivatives and branched amino acids |
Non-Patent Citations (37)
Title |
---|
A. PEGOVA ET AL., COMP. BIOCHEM. PHYSIOL. B. BIOCHEM. MOL. BIOL., vol. 127, no. 4, 2000, pages 443 |
A.A. BOLDYREV, A.Y. DUPIN, M.A. BABIZHAYEV, S.E. SEVERIN, BIOCHEM. INT., vol. 15, 1987, pages 1105 |
A.A. BOLDYREV, S.E. SEVERIN, ADV. ENZYME REGUL., vol. 30, 1990, pages 175 |
ANN. NY ACAD. SCI., vol. 854, 1998, pages 37 |
BABIZHAYEV M.A.: "Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens", BIOCHIM. BIOPHYS. ACTA, vol. 1004, 1989, pages 363 - 371, XP023577765, DOI: doi:10.1016/0005-2760(89)90085-4 |
D.S. MOTTRAM ET AL., NATURE, vol. 419, 2002, pages 448 |
ENCEPHALE, vol. 28, no. 2, 2002, pages 147 |
F. MARGOLIS, SCIENCE, vol. 184, 1974, pages 909 |
J.H. KANG ET AL., MOLECULES AND CELLS, vol. 13, 2002, pages 107 |
J.J. O'DOWD ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 967, 1988, pages 241 |
J.L. JAY ET AL., MEETING ABSTR. J. PHYSIOL. LOND., vol. 420, 1990, pages 155 |
JACKSON ET AL., CLIN. CHIM. ACTA, vol. 196, 1991, pages 193 |
JAY ET AL., MEETING ABSTR. J. PHYSIOL., vol. 420, 1990, pages 155 |
K. NAGAI, LANGENBECKS ARCH. CHIR., vol. 351, 1980, pages 39 |
K.G.CRUSH, COMP. BIOCHEM. PHYSIOL., vol. 34, 1970, pages 3 |
L . FLANCBAUM ET AL., LIFE SCI., vol. 47, 1990, pages 1587 |
LENNEY ET AL., BIOCHEM. J., vol. 228, 1985, pages 653 |
LENNEY J.F. ET AL: "Human Cytosolic Carnosinase: Evidence of Identity with Prolinase, a Non-specific Dipeptidase", BIOLOGICAL CHEMISTRY HOPPE-SEYLER, vol. 371, no. 2, 1990, pages 167 - 171, XP002979351 * |
M. A. BABIZHAYEV ET AL., BIOCHEM. J., vol. 304, 1994, pages 509 |
M. DUNNETT, R.C. HARRIS, J. CHROMATOGRAPHY B, vol. 688, 1997, pages 47 |
M.A. BABIZHAYEV ET AL., BIOCHEM. J., vol. 304, 1994, pages 509 |
M.A. BABIZHAYEV ET AL., BIOCHEMISTRY (MOSCOW, vol. 63, 1998, pages 523 |
M.A. BABIZHAYEV ET AL., BIOCHEMISTRY (MOSCOW, vol. 63, 1998, pages 620 |
M.A. BABIZHAYEV ET AL., CLINICA CHIMICA ACTA, vol. 254, 1996, pages 1 |
M.A. BABIZHAYEV ET AL., LETTERS IN PEPTIDE SCIENCE, vol. 5, 1998, pages 163 |
M.C. JACKSON ET AL., CLIN. CHIM. ACTA, vol. 196, 1991, pages 193 |
P.R. CARNEGIE ET AL., J. CHROMATOGR., vol. 261, 1983, pages 153 |
PEPPERS S.C. ET AL: "Bestatin Inhibition of Human Tissue Carnosinase, a Non-Specific Cytosolic Dipeptidase", BIOLOGICAL CHEMISTRY HOPPE-SEYLER, vol. 369, no. 12, 1988, pages 1281 - 1286, XP002979350 * |
R. HOLLIDAY, G.A. MCFARLAND., BIOCHEMISTRY (MOSCOW, vol. 65, 2000, pages 843 |
R.C. HARRIS ET AL., COMP. BIOCHEM. PHYSIOL., vol. 97A, 1990, pages 249 |
R.H. STADLER ET AL., NATURE, vol. 419, 2002, pages 449 |
S.C. PEPPERS, J.F. LENNEY, BIOL. CHEM. HOPPE SEYLER, vol. 369, 1988, pages 1281 |
SEKINE ET AL., INT. J. CANCER, vol. 94, 2001, pages 485 |
T. YAMANE ET AL., J. NIHON UNIV. SCHOOL. DENT., vol. 19, 1977, pages 70 |
T.A. DAHL, W.R. MIDDEN, P.E. HARTMAN, PHOTOCHEM. PHOTOBIOL., vol. 47, 1988, pages 357 |
Y. COURBEBAISSE, G. LANGRAND, J-F. NICOLAY, M.A. BABIZHAYEV, PROCEEDING OF 19TH IFSCC CONGRESS, vol. 3, 1996, pages 1 - 12 |
Y. SUZUKI ET AL., JAPAN. J OF PHYSIOL., vol. 64, 2002, pages 199 |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291599B2 (en) | 2003-08-12 | 2007-11-06 | Keyneurotek Ag | Use of inhibitors of enzymes having activities of amino peptidase N and/or dipeptidyl peptidase IV and of pharmaceutical preparations thereof for a therapy and prevention of chronical neurodegenerative diseases |
EP1506776A1 (de) * | 2003-08-12 | 2005-02-16 | KeyNeurotek AG | Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention von chronischen neurodegenerativen Erkrankungen |
CN101175470B (zh) * | 2005-05-09 | 2011-09-14 | 株式会社资生堂 | 角化不全抑制剂、毛孔收缩剂和皮肤外用组合物 |
JP2006312597A (ja) * | 2005-05-09 | 2006-11-16 | Shiseido Co Ltd | 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物 |
WO2006120941A1 (ja) * | 2005-05-09 | 2006-11-16 | Shiseido Company, Ltd. | 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物 |
US8937090B2 (en) | 2005-05-09 | 2015-01-20 | Shiseido Company, Ltd. | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin |
KR101338982B1 (ko) * | 2005-05-09 | 2013-12-10 | 가부시키가이샤 시세이도 | 부전각화 억제제, 모공 축소제 및 피부 외용 조성물 |
US7776364B2 (en) | 2006-03-24 | 2010-08-17 | Advanced Scientific, Llc | Non-surgical method for treating cataracts in mammals including man |
JP2009120564A (ja) * | 2007-11-16 | 2009-06-04 | Maruha Nichiro Foods Inc | ヒアルロン酸産生促進物質 |
WO2010005077A1 (ja) * | 2008-07-11 | 2010-01-14 | 財団法人ヒューマンサイエンス振興財団 | パーキンソン病の疾患関連たんぱく質およびその使用 |
JP2010208989A (ja) * | 2009-03-10 | 2010-09-24 | Fancl Corp | 抗不安剤 |
JPWO2011078204A1 (ja) * | 2009-12-24 | 2013-05-09 | 浜理薬品工業株式会社 | 高脂血症の予防または治療剤、および抗疲労剤 |
WO2011078204A1 (ja) * | 2009-12-24 | 2011-06-30 | 浜理薬品工業株式会社 | 高脂血症の予防または治療剤、および抗疲労剤 |
JP2012021026A (ja) * | 2011-10-07 | 2012-02-02 | Shiseido Co Ltd | 不全角化抑制剤、毛穴縮小剤及び肌荒れ防止・改善剤 |
JP2013176327A (ja) * | 2012-02-28 | 2013-09-09 | Sapporo Breweries Ltd | 麦芽飲料、香味改善剤及びこれらに関する方法 |
US9375398B2 (en) | 2013-03-13 | 2016-06-28 | Neocutis S.A. | Peptides for skin rejuvenation and methods of using the same |
WO2014140890A2 (en) | 2013-03-13 | 2014-09-18 | Neocutis Sa | Peptides for skin rejuvenation and methods of using the same |
US10543195B2 (en) | 2013-03-13 | 2020-01-28 | Anteis Sa | Peptides for skin rejuvenation and methods of using the same |
US11331305B2 (en) | 2013-03-13 | 2022-05-17 | Anteis Sa | Peptides for skin rejuvenation and methods of using the same |
WO2017104777A1 (ja) * | 2015-12-16 | 2017-06-22 | サントリーホールディングス株式会社 | カルノシンジペプチダーゼ阻害用組成物 |
JPWO2017104777A1 (ja) * | 2015-12-16 | 2018-10-04 | サントリーホールディングス株式会社 | カルノシンジペプチダーゼ阻害用組成物 |
CN108578678A (zh) * | 2018-03-13 | 2018-09-28 | 孟斯琴 | 一种抗癫痫药物组合物及其制备方法 |
WO2022167569A1 (en) * | 2021-02-04 | 2022-08-11 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic composition |
Also Published As
Publication number | Publication date |
---|---|
US20060116328A1 (en) | 2006-06-01 |
EP1586332A4 (en) | 2009-11-11 |
JPWO2004064866A1 (ja) | 2006-05-18 |
JP2014012735A (ja) | 2014-01-23 |
EP1586332A1 (en) | 2005-10-19 |
JP2011068652A (ja) | 2011-04-07 |
US20140086855A1 (en) | 2014-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014012735A (ja) | カルノシナーゼ阻害剤とl−カルノシン類との併用および組成物 | |
Prokopieva et al. | Use of carnosine for oxidative stress reduction in different pathologies | |
Packer | Interactions among antioxidants in health and disease: vitamin E and its redox cycle | |
KR100617929B1 (ko) | 환원된 조효소 q 의 안정한 용액 | |
TWI245628B (en) | Stabilized composition of reduced coenzyme Q10 aqueous solution | |
US20060228395A1 (en) | Vitamin E phosphate/phosphatidylcholine liposomes to protect from or ameliorate cell damage | |
KR100489371B1 (ko) | 산화성스트레스로발생한심혈관계및신경계통질환의예방과치료에유용한l-카르니틴,이들의유도체및항산화제의용도 | |
US20100061969A1 (en) | Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic | |
WO2011078204A1 (ja) | 高脂血症の予防または治療剤、および抗疲労剤 | |
US20050181021A1 (en) | Vitamin E phosphate/phosphatidycholine liposomes to protect from or ameliorate cell damage | |
RU2288707C2 (ru) | Антиатеросклеротическая композиция, содержащая каротиноиды, и способ ингибирования окисления липопротеина низкой плотности (ldl) | |
US6576266B1 (en) | Plant extract based on glycerides, a method for the preparation of this extract and a cosmetic composition containing the same | |
WO1993015731A1 (en) | Phosphate derivatives of vitamin e to protect cells from effects of aging and injury | |
EP2136777A2 (fr) | Utilisation de la citrulline pour le traitement de pathologies liees a une augmentation de la carbonylation des proteines | |
JP2008504231A (ja) | 酸化ジベンゾ−アルファ−ピロン色素タンパク質 | |
WO2001012141A1 (fr) | Stimulants pour la pousse de cheveux | |
Biagi et al. | The effect of dietary polyenylphosphatidylcholine on microsomal delta-6-desaturase activity, fatty acid composition, and microviscosity in rat liver under oxidative stress | |
EP2452577B1 (fr) | Solution aqueuse de phytine et utilisation de ladite solution pour la préparation d'un complément alimentaire liquide ou d'une composition cosmétique | |
JP5468758B2 (ja) | セラミド類含有組成物 | |
US20050233942A1 (en) | Oxygenated dibenzo-alpha-pyrone chromoproteins | |
KR20180011310A (ko) | 미백 화장료 조성물 | |
JP2000072686A (ja) | 活性酸素消去剤およびこれを含有する組成物 | |
KR20170107256A (ko) | 미백 화장료 조성물 | |
KR20090119085A (ko) | 안토시아닌을 포함하는 자외선 조사에 의해 유도된아팝토시스 억제용 조성물 | |
Sies et al. | Antioxidants and human health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
REEP | Request for entry into the european phase |
Ref document number: 2004702856 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004702856 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006116328 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005508063 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10542109 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004702856 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10542109 Country of ref document: US |